

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 48/00, 39/395, 38/00, 35/00, C12N 15/63, 15/85, 15/86		A1	(11) International Publication Number: WO 99/61065 (43) International Publication Date: 2 December 1999 (02.12.99)
(21) International Application Number: PCT/US99/11419		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 21 May 1999 (21.05.99)		Published <i>With international search report.</i>	
(30) Priority Data: 60/086,625 23 May 1998 (23.05.98) US			
(71) Applicants: LEIDEN UNIVERSITY MEDICAL CENTER [NL/NL]; Dept. of Immunohematology and Bloodbank, Albinusdreef 2, P.O. Box 9600, NL-Leiden (NL). TANOX, INC. [US/US]; 10301 Stella Link, Houston, TX 77025 (US).			
(72) Inventors: MELIEF, Cornelis, J., M.; Wilhelmina park 33, NL-2012 KC Haarlem (NL). OFFRINGA, Rienk; Stichtesstraat 63, NL-2313 SJ Leiden (NL). TOES, Rene; Marco Polostraat 73 III, NL-1057 WN Amsterdam (NL). SCHOENBERGER, Stephen, P.; 259 Coneflower Street, Encinitas, CA 92024 (US). DE BOER, Mark; NL-1261 BT Blaricum (NL).			
(74) Agent: MIRABEL, Eric; 10301 Stella Link, Houston, TX 77025 (US).			
(54) Title: CD40 BINDING MOLECULES AND CTL PEPTIDES FOR TREATING TUMORS			
(57) Abstract			
<p>Disclosed is a method and composition for treating tumors or infectious diseases, wherein the composition includes CD40 binding molecules together with CTL-activating peptides, e.g., tumor antigens. Such composition is useful for enhancing the anti-tumor effect of a peptide tumor vaccine, or for otherwise activating CTLs so that the activated CTLs can act against tumorous or infected cells. The CD40 binding molecules can include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, (Fab')₂ and Fv, as well as other molecules including peptides, oligonucleotides, peptidomimetics and organic compounds which bind to CD40 and activate the CTL response.</p>			